Cardium(now called Gene Biotherapeutics) sold the product to another company Olaregen. Cardium is not good at packaging and marketing and wanted to monetize the product. Olaregen began redeveloping the product in a way it would be user friendly for prescibing and treatment and imo, better reimbursed by third parties. While this was being developed they became a sub of GNBT.